Related Experiment Video
Updated: May 6, 2026
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Dual-targeting tigecycline nanoparticles for treating intracranial infections caused by multidrug-resistant
Xing Lan1,2, Shugang Qin1, Huan Liu1
1Department of Critical Care Medicine, Department of Clinical Pharmacy, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China School of Nursing, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
Multidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) is a formidable pathogen responsible for severe intracranial infections post-craniotomy, exhibiting a mortality rate as high as 71%. Tigecycline (TGC), a broad-spectrum antibiotic, emerged as a potential therapeutic agent for MDR A. baumannii infections. Nonetheless, its clinical application was hindered by a short in vivo half-life and limited permeability through the blood-brain barrier (BBB). In this study, we prepared a novel core-shell nanoparticle encapsulating water-soluble tigecycline using a blend of mPEG-PLGA and PLGA materials. This nanoparticle, modified with a dual-targeting peptide Aβ11 and Tween 80 (Aβ11/T80@CSs), was specifically designed to enhance the delivery of tigecycline to the brain for treating A. baumannii-induced intracranial infections. Our findings demonstrated that Aβ11/T80@CSs nanocarriers successfully traversed the BBB and effectively delivered TGC into the cerebrospinal fluid (CSF), leading to a significant therapeutic response in a model of MDR A. baumannii intracranial infection. This study offers initial evidence and a platform for the application of brain-targeted nanocarrier delivery systems, showcasing their potential in administering water-soluble anti-infection drugs for intracranial infection treatments, and suggesting promising avenues for clinical translation.
Insights
Novel nanoparticles effectively deliver tigecycline across the blood-brain barrier to treat multidrug-resistant Acinetobacter baumannii brain infections, offering a promising new therapeutic strategy.
Area of Science:
- Neuroscience
- Infectious Diseases
- Nanotechnology
Background:
- Multidrug-resistant Acinetobacter baumannii causes severe intracranial infections with high mortality.
- Tigecycline shows potential but faces challenges with blood-brain barrier penetration and short half-life.
Purpose of the Study:
- To develop a novel brain-targeted nanocarrier system for enhanced tigecycline delivery to treat Acinetobacter baumannii intracranial infections.
Main Methods:
- Core-shell nanoparticles encapsulating tigecycline were prepared using mPEG-PLGA and PLGA.
- Nanoparticles were modified with dual-targeting peptide Aβ11 and Tween 80 (Aβ11/T80@CSs) for enhanced brain targeting.
- Efficacy was evaluated in a model of multidrug-resistant Acinetobacter baumannii intracranial infection.
Main Results:
- Aβ11/T80@CSs nanocarriers successfully crossed the blood-brain barrier.
- Effective delivery of tigecycline into the cerebrospinal fluid was achieved.
- Significant therapeutic response was observed in the infection model.
Conclusions:
- Brain-targeted nanocarrier systems show potential for delivering water-soluble drugs for intracranial infections.
- This platform offers a promising strategy for treating multidrug-resistant Acinetobacter baumannii brain infections.
- Further clinical translation is suggested for these nanodelivery systems.
